October 1, 2026

InterDigital, Inc. (IDCC) Stock Analysis: Exploring a 41.89% Potential Upside with Robust Technological Innovations

InterDigital, Inc. (NASDAQ: IDCC) stands as a beacon of innovation in the Technology sector, specifically within the Software – Application industry. With a market capitalization of $8.41 billion, this Delaware-based..

A2Z Cust2Mate Solutions Corp. (AZ) Investor Outlook: Unpacking a 291% Upside Potential

Investors seeking exposure to innovative technology companies may want to take a closer look at A2Z Cust2Mate Solutions Corp. (AZ), a Canadian firm making waves in the Software – Application..

Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Exploring a 69.47% Potential Upside in the mRNA Medicine Revolution

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a San Diego-based biotechnology firm, stands at the forefront of innovative mRNA-based therapeutics. Despite a challenging financial landscape, the company is generating buzz among..

Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Exploring a 19.38% Potential Upside in Revolutionary Cancer Therapy

Investors with an eye on the biotechnology sector should consider the promising opportunity presented by Alpha Tau Medical Ltd. (NASDAQ: DRTS). This Israel-based company is making waves in the healthcare..

Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Navigating Challenges in the Biotechnology Sector

Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, is carving its niche in the biotechnology sector by developing small molecules aimed at treating genetically defined..

Grab Holdings Limited (GRAB) Stock Report: A Promising 85% Potential Upside for Tech Investors

Grab Holdings Limited (NASDAQ: GRAB) is making waves in the technology sector, offering a robust suite of services through its superapp. As the company continues to expand its footprint across..

Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis: A Biotech with 322% Upside Potential

Investors with a keen eye on the biotechnology sector may find Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) an intriguing prospect, given its significant upside potential and focused approach in targeting women’s..

Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Potential 424% Upside in the Biotech Sector

Compass Therapeutics, Inc. (NASDAQ: CMPX) is a clinical-stage biopharmaceutical company that has caught the attention of investors with its innovative approach to oncology therapeutics. Focused on developing antibody-based treatments, Compass..

Alumis Inc. (ALMS) Stock Analysis: Exploring a 335% Potential Upside in Biotech Innovation

For investors with an appetite for high-growth opportunities in the biotechnology sector, Alumis Inc. (NASDAQ: ALMS) presents a compelling case. The clinical-stage biopharmaceutical company, headquartered in South San Francisco, is..

Porch Group, Inc. (PRCH) Stock Analysis: Exploring a 24.76% Upside Potential in the Insurance Tech Space

Porch Group, Inc. (NASDAQ: PRCH) stands at the intriguing intersection of technology and insurance, offering a suite of services that cater to the intricacies of homeownership. Despite facing a challenging..

ServiceTitan, Inc. (TTAN) Stock Analysis: Unveiling a 48% Potential Upside in the Tech Sector

For investors with an eye on the technology sector, ServiceTitan, Inc. (NASDAQ: TTAN) presents an intriguing opportunity. With a market capitalization of $6.35 billion, this software application company is carving..

Quhuo Limited (QH) Stock Analysis: Navigating Challenges with a $325.71 Billion Market Cap

Quhuo Limited (NASDAQ: QH) operates within the dynamic and rapidly evolving software application industry. Based in Beijing, China, Quhuo provides comprehensive workforce operational solutions, catering to a diverse range of..

Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a Promising 108% Upside in Oncology Innovations

Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company, is capturing significant attention in the biotechnology sector with its promising advancements in cancer immunotherapies. Headquartered in Needham, Massachusetts, Candel focuses on..

UroGen Pharma Ltd. (URGN) Stock Analysis: A Potential 47.67% Upside in the Biotech Sector

UroGen Pharma Ltd. (NASDAQ: URGN), a prominent player in the biotechnology sector, is attracting investor attention with its promising outlook and a potential upside of 47.67%, as suggested by its..

Fair Isaac Corporation (FICO) Stock Analysis: Unveiling a Potential 112% Upside with Robust Revenue Growth

Fair Isaac Corporation (NYSE: FICO), a prominent player in the technology sector, commands a strong presence in the software application industry. Headquartered in Bozeman, Montana, FICO is renowned for its..

Nyxoah SA (NYXH) Stock Analysis: Unveiling a Potential 205% Upside for Investors

For investors seeking opportunities in the healthcare sector, Nyxoah SA (NASDAQ: NYXH) presents a compelling case. As a Belgium-based medical technology company, Nyxoah is at the forefront of developing innovative..

Chevron Corporation (CVX) Stock Analysis: Evaluating a 9.79% Potential Upside Amid Robust Revenue Growth

Chevron Corporation (CVX), a titan in the integrated oil and gas industry, commands investor attention with its expansive operations that span the globe. From its headquarters in Houston, Texas, Chevron..

Senseonics Holdings, Inc. (SENS) Stock Analysis: Exploring a 39.63% Potential Upside

Investors with a keen eye on the healthcare sector might find Senseonics Holdings, Inc. (NASDAQ: SENS) an intriguing proposition. As a commercial-stage medical technology company, Senseonics is at the forefront..

Viant Technology Inc. (DSP) Stock Analysis: Unpacking a 58% Upside Potential Amid Strong Buy Ratings

Viant Technology Inc. (NASDAQ: DSP) is currently garnering significant attention from investors, largely due to its promising position in the technology sector, specifically in the software-application industry. As a cloud-based..

Gossamer Bio, Inc. (GOSS) Stock Analysis: Unveiling a Potential 596% Upside

Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, is capturing investor interest with its staggering potential upside of 596.03%, according to analyst ratings. This San Diego-based biotechnology firm is..

Search

Funds

October 1, 2026

Search

Funds

October 1, 2026

FTSE 100

Funds